Response rates to PD-1/PD-L1 inhibitors vary among different cancer types, and not all patients respond to treatment. Furthermore, some tumors may utilize alternative immune evasion mechanisms, limiting the efficacy of PD-1/PD-L1 blockade alone. The gene discussed is PDCD1; the disease is cancer.